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Objective: We sought to define the long-term outcome of surgically treated solitary fibrous tumors of the pleura.
Methods: We performed a retrospective review from December 1972 through December 2002.
Results: There were 84 patients (39 men and 45 women) with a median age of 57 years (range, 34–83 years).
Forty-six patients were symptomatic. Surgical resection included pulmonary wedge excision in 62 patients,
lobectomy in 4 patients, segmentectomy in 2 patients, chest wall resection in 3 patients, isolated pleural resection
in 7 patients, and chest wall resection with pulmonary wedge excision, lobectomy, or pneumonectomy in 3, 2, and
1 patients, respectively. Tumors were polypoid in 57 patients, sessile in 20 patients, and intrapulmonary in 7
patients. Histopathology was benign in 73 and malignant in 11 patients. Nine (82%) patient with malignant
tumors and 37 (54%) patients with benign tumors were symptomatic (P ¼ .11). The median tumor diameters
for malignant and benign tumors were 12.0 and 4.5 cm, respectively (P ¼ .001). Operative mortality and mor-
bidity occurred in 3 (3.6%) and 7 (8.1%) patients, respectively. Median follow-up in survivors was 146 months
(range, 23–387 months). Median survival for patients with benign and malignant tumors was 284 and 55 months,
respectively, and 5-year survival was 88.9% and 45.5%, respectively (P ¼ .0005). Eight (9.5%) patients had
recurrent solitary fibrous tumors of the pleura. Recurrences were malignant in 6 and benign in 2 patients. Local-
ized chest recurrences occurred in 3 patients, all of whom had reresection, with 2 patients again having recurrence.
Conclusion: Resection of benign solitary fibrous tumors of the pleura carries an excellent prognosis. Larger
tumors are more likely to be malignant. Both benign and malignant tumors can recur. Although prolonged sur-
vival after resection of malignant tumors is possible, recurrence is common.Solitary fibrous tumors of the pleura (SFTPs) are rare mesen-
chymal tumors most commonly arising in the pleura. They
can, however, also present as an intrapulmonary mass.1
SFTPs are distinct from diffuse malignant mesothelioma
(DMM), which is associated with asbestos exposure and
typically carries a poor prognosis.2 The histopathologic char-
acteristics of SFTPs were first described by Klemperer and
Rabin in 1931.3 Over the years, SFTPs have been character-
ized by a number of terms, including fibrous mesothelioma,
localized fibrous mesothelioma, localized mesothelioma,
localized fibrous tumors, fibrous mesothelioma, solitary
fibrous mesothelioma, pleural fibroma, submesothelial fi-
broma, and subserosal fibroma.4 The absence of clear nomen-
clature has only added to the confusion about these tumors,
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doi:10.1016/j.jtcvs.2009.01.026The Journal of Thoracic andand uncertainty exists with regard to their clinical behavior.
The purpose of this report is to review our experi-ence with
patients who underwent surgical resection for SFTPs.
MATERIALS AND METHODS
Between December 1972 and December 2002, 84 patients underwent
surgical treatment for SFTPs at the Mayo Clinic in Rochester, Minnesota,
and these patients formed the basis for this review. The study was approved
by the Mayo Foundation’s Institutional Review Board. Medical records
were analyzed for age, sex, signs and symptoms, radiographic findings,
tumor histopathology, location, surgical resection, clinical outcome, and
survival. Operative mortality included patients who died within the first
30 days after surgical intervention or during the same hospital admission.
Follow-up was obtained from retrospective review of the patients’ medical
records and, where necessary, written surveys. Malignant SFTPs were diag-
nosed when more than 4 mitoses per 10 high-power fields were seen on light
microscopic analysis.5 Additional microscopic supportive features of malig-
nancy included areas of hemorrhage and necrosis, areas of high cellularity
with crowding and overlapping nuclei, marked pleomorphism, and vascular
invasion.5 The probability of survival and the cumulative probability of
recurrence were estimated by using the Kaplan–Meier survivorship
method.6 Recurrence and survival were estimated starting at the date of
the first SFTP resection and are reported with 95% confidence intervals
(CIs). Survival curves of the patients were compared with expected curves
of persons of the same age and sex, as derived from vital statistics for the
west–north–central region of the United States.7 Comparisons of survivor-
ship curves were made with 1-sample log-rank tests.8 Comparisons of dis-
crete variables between benign and malignant pathology were made with
Fisher’s exact tests.9 Comparisons of continuous variables between benignCardiovascular Surgery c Volume 138, Number 1 19
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CI ¼ confidence interval
CT ¼ computed tomography
DMM ¼ diffuse malignant mesothelioma
FNA ¼ fine-needle aspiration
PET ¼ positron emission tomography
SFTP ¼ solitary fibrous tumor of the pleura
VATS ¼ video-assisted thoracic surgery
and malignant pathology were made with Wilcoxon rank sum tests.10 All
statistical tests were 2-sided.
RESULTS
There were 45 women and 39 men with a median age
of 57 years (range, 34–83 years) enrolled in the study.
Forty-five (54%) patients had a positive history of cigarette
smoking. Median pack-years were 30 (range, 1–100 pack-
years). Forty-six (55%) patients were symptomatic, with
chest pain in 15 (18%), cough in 8 (9.5%), dyspnea in
3 (3.6%), and various other symptoms in 12 (14%). Eight
(9.5%) patients had multiple symptoms. Extrathoracic
symptoms, such as hypertrophic pulmonary osteoarthrop-
athy alone in 3 (3.6%) patients, hypertrophic pulmonary
osteoarthropathy and digital clubbing in 5 (6.0%) patients,
and hypoglycemia in 1 (1.2%) patient, were present. Chest
radiographs were obtained for the entire study group, and
the SFTPs were identified in 77 (92%) patients. Before use
of computed tomographic (CT) analysis, conventional chest
tomographic scans were obtained in 15 (18%) patients, and
the SFTPs were visualized in all. Sixty-two (74%) patients
had CT scans of the chest, with the SFTPs visualized in 61
(98%). Magnetic resonance imaging was obtained in 4
(4.8%) patients, and results were abnormal in all. The SFTPs
occurred on the right side in 50 (60%) patients and the left
side in 34 (40%) patients. CT-guided percutaneous biopsies
were performed in 22 (26%) patients and were diagnostic in
10 (45%) patients. Transbronchial biopsies were performed
in 3 (3.6%) patients and were diagnostic in 1 (33%) patient.
All patients underwent surgical treatment. Postoperative
chemotherapy and chemoradiotherapy were administered
to 1 patient each. The operative approach was a posterolat-
eral thoracotomy in 68 (81%) patients, video-assisted tho-
racic surgery (VATS) in 12 (14%) patients, a sternotomy
in 3 (3.6%) patients, and a transabdominal approach in 1
(1.2%) patient. The transabdominal approach was used for
a paraesophageal hiatal mass, which at the time of surgical
intervention proved to be an SFTP that was able to be
resected through this approach. The SFTPs were polypoid
in 57 (68%) patients, sessile in 20 (24%) patients, and intra-
pulmonary in 7 (8.3%) patients. At the time of the operation,
the SFTPs appeared to arise from the visceral pleura in 58
(69%) patients, the parietal pleura in 15 (18%) patients,20 The Journal of Thoracic and Cardiovascular Surgand both in 4 (4.8%) patients and were intrapulmonary with-
out obvious visceral pleural involvement in 7 (8.3%) patients.
Surgical resection was pulmonary wedge excision in 62
(74%) patients, lobectomy in 4 (4.8%) patients, segmentec-
tomy in 2 (2.4%) patients, isolated parietal pleural resection
alone in 7 (8.3%) patients, chest wall resection alone in 3
(3.6%) patients, and chest wall resection combined with
concomitant pulmonary wedge excision, lobectomy, or pneu-
monectomy in 3, 2, and 1 patients, respectively. SFTP resection
was complete in all patients. SFTPs were benign in 73 (87%)
patients and malignant in 11 (13%) patients. Nine (82%)
patients with malignant SFTPs and 37 (54%) patients with
benign SFTPs were symptomatic (P ¼ .11). Morphologically
benign SFTPs were polypoid, sessile, and intraparenchymal
in 51 (70%), 15 (20%), and 7 (10%) patients, respectively.
Similarly, malignant SFTPs were polypoid and sessile in 4
(36%) and 7 (64%) patients, respectively. Morphologic and
pleural characteristics of the SFTPs are shown in Table 1. Nei-
ther the morphologic characteristics nor the site of pleural origin
aided in the differentiation of benign from malignant SFTPs
(P¼ .08). The median overall tumor diameter was 5 cm (range,
0.8–30 cm). The median diameter was 12 cm (range, 7–19 cm)
for malignant SFTPs and 4.5 cm (range, 0.8–30 cm) for benign
SFTPs (P¼ .001). In 7 (64%) of the 11 patients with malignant
SFTPs, the tumor diameter was greater than 10 cm, whereas the
tumor was greater than 10 cm in only 17 (23%) of the 73
patients with benign SFTPs (P¼ .01).
Mediastinal lymphadenectomy or lymph node sampling
was performed at the individual discretion of the surgeon
in 11 (13%) patients. Four of these patients had recurrent
SFTPs, and 6 had malignant tumors. Mediastinal lymph
node removal was undertaken on larger SFTPs with a median
diameter of 7.5 cm (range, 1.5–19 cm). On histopathologic
examination, no tumor was found in any of the lymph nodes.
Complications occurred in 9 (11.8%) patients and included
atrial fibrillation, bleeding, and reoperation for bleeding in 2
(2.4%) patients each and pleural effusion, pneumonia, and
postoperative ileus in 1 (1.2%) patient each.
Three patients died (operative mortality, 3.6%). One
patient with no prior history of coronary artery disease
TABLE 1. Characteristics of solitary fibrous tumors of the pleura
Benign,
no. of
patients (%)
Malignant,
no. of
patients (%) P value*
Recurrence,
no. of
patients
Morphology .17
Polypoid 51 (70) 6 (55) 5 (88)
Sessile 14 (19) 5 (45) 3 (16)
Intrapulmonary 8 (11) 0
Pleura .08
Parietal 12 (16) 3 (27) 2 (13)
Visceral 51 (70) 6 (55) 3 (53)
Both 2 (3) 2 (18) 3 (75)
Intrapulmonary 8 (11) 0
*Fisher’s exact test.ery c July 2009
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tion. The second patient had known renal insufficiency and
severe atherosclerosis and died on postoperative day 9 of
mesenteric ischemia. The final patient had been discharged
without complication from the hospital on postoperative
day 7 and died of unknown cause on postoperative day 12
at home.
Follow-up was complete in all survivors and ranged from 2 to
32 years (median, 12 years). At last follow-up, 56 patients were
alive, and 27 had died. The overall 5-year survival was 83%
(95% CI, 75%–92%), with a median survival of 284 months
and an expected survival of 91% (P¼ .19, Figure 1). Median
survival for malignant SFTPs was 55 versus 284 months for
benign SFTPs. Five-year survival for benign and malignant
SFTPs was 89% (95% CI, 82%–96%) and 45.5% (95%
CI, 24%–87%), respectively (P¼ .0005, Figure 2).
Overall, 5-year freedom from recurrence was 95% (95%
CI, 90%–100%). Of 81 operative survivors, 8 (9.9%)
patients experienced recurrent SFTPs. For patients experienc-
ing recurrence, the surgical approach was a thoracotomy in
7 patients and a median sternotomy in 1 patient. The site of
pleural origin for recurrent SFTPs was visceral in 4 patients,
parietal in 2 patients, and both in 2 patients. Five-year
freedom from recurrence for patients with benign and malig-
nant SFTPs was 100% and 58% (95% CI, 34%–100%),
respectively (P < .0001, Figure 3). Ultimately, 6 (75%)
patients with malignant SFTPs and 2 (25%) patients with
benign SFTPs experienced recurrence. Median time to recur-
rence for malignant and benign SFTPs was 34 and 83 months,
respectively. In the 6 patients with initially malignant SFTPs
that recurred, the recurrences were malignant in 5 patients
and benign in 1 patient. In the 2 patients with benign SFTPs
that recurred, the recurrence was benign and malignant in 1 pa-
tient each. Recurrences were localized in 3 (37.5%) patients
and widely metastatic in 5 (62.5%) patients. All 3 patients
FIGURE 1. Overall survival (death from any cause) of 84 patients under-
going resection of solitary fibrous tumors of the pleura. Zero time on the
abscissa is the date of the operation. Numbers of patients at risk are shown
below the abscissa.The Journal of Thoracic andwith localized recurrences underwent reresection, and 2
STFPs again recurred. The SFTP recurrence was diffusely
metastatic within the abdominal cavity and localized to the ip-
silateral hemithorax in 1 patient each. The latter patient even-
tually underwent a total of 4 resections over a 24-year period,
after which he remained without evidence of disease. In the 5
patients with widely metastatic recurrent SFTPs, the observed
sites of distant metastases included bone, contralateral hemi-
thorax, liver, peritoneum, and retroperitoneum.
DISCUSSION
SFTPs are uncommon neoplasms, with just over 900
cases reported in the literature.4,11 Although SFTPs were
FIGURE 2. Survival (death from any cause) in 73 patients who underwent
resection of benign solitary fibrous tumors of the pleura compared with that
in 11 patients who had resection of malignant solitary fibrous tumor. Zero
time on the abscissa is the date of the operation. Numbers of patients at
risk are shown below the abscissa.
FIGURE 3. Survival (death from any cause) free of recurrence in 73 pa-
tients who underwent resection of benign solitary fibrous tumors of the
pleura compared with that in 11 patients who had resection of malignant sol-
itary fibrous tumors. Zero time on the abscissa is the date of the operation.
Numbers of patients at risk are shown below the abscissa.Cardiovascular Surgery c Volume 138, Number 1 21
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leagues,12 from our institution, in 1978 emphasized their
malignant potential. Nevertheless, because of a lack of
understanding of the cellular origins of SFTPs and their
seemingly indolent clinical course, many physicians still
consider SFTPs to be a benign variant of mesothelioma.13
Localized mesothelioma of the pleura was first described
by Wagner in 1870.12 In 1931, Klemperer and Rabin3 distin-
guished localized mesothelioma from diffuse mesothelioma
and proposed submesothelial cells as the cellular origin for
the localized variety. Controversy developed in 1941,
when Stout and Murray14 claimed mesothelial cells to be
the cellular origin of localized mesothelioma. More recently,
immunohistochemical techniques, flow cytometric studies,
and electron microscopic analysis have demonstrated that
SFTPs indeed arise from the mesenchymal cells beneath
the mesothelial lining of the pleura, as initially postulated
by Klemperer and Rabin.2-4,11,15,16 This mesothelial versus
mesenchymal difference in cell origin is likely key to the
wide dissemination of DMM over serosal surfaces, eventu-
ally leading to organ encasement, in contrast to the more
localized spread of SFTPs. Based on this differentiation in
cellular origin, the term localized mesothelioma has been
abandoned in favor of SFTPs.17 SFTPs have no known asso-
ciation with asbestos exposure. DMM, unlike SFTPs, has
a poor clinical course, with death often occurring within
2 years of diagnosis. Immunohistochemistry is a useful
adjunct in the differentiation of SFTPs from DMM. SFTPs,
in distinction to DMM, stain positive for vimentin and
CD34 and negative for keratin. Table 2 outlines the distinct
immunohistochemical profile of SFTPs and DMM.
Our series, like others, show SFTPs to most commonly
arise in the sixth decade of life. Although some authors
have stated that SFTPs are seen equally in men and
women,4,15 our large series and others11,12,18 show a predilec-
tion for women. Approximately half of patients are symptom-
atic on presentation, and symptoms are more common in
patients with malignant SFTPs. Common symptoms include
chest pain and cough. Extrathoracic symptoms, such as
hypertrophic pulmonary osteoarthropathy, clubbing, and
hypoglycemia, have been reported in up to 66% of
patients12,19,20 but occurred in only 9 (11%) of our patients.
This frequency of symptoms is less than both the 66% and
19% frequencies reported in our earlier series12,19 but still
greater than the frequencies reported in most recent series
from other institutions.11,16,18 The extrathoracic symptoms
TABLE 2. Immunohistochemical profile of SFTPs and diffuse
malignant mesothelioma
Tumor Cytokeratin Vimentin CD34 CD99 Bcl-2
SFTP  þ þ þ þ
DMM þ    
SFTP, Solitary fibrous tumor of the pleura;, negative;þ, positive; DMM, diffuse
malignant mesothelioma.22 The Journal of Thoracic and Cardiovascular Surgresolved in all of our patients after surgical resection. Chest
CT scanning is the radiographic test of choice, often showing
a well-circumscribed homogenous mass of soft tissue attenu-
ation; however, this finding lacks specificity, and heterogene-
ity is possible (Figures 4 and 5). The tumors commonly show
displacement of surrounding structures, although some might
appear as intraparenchymal masses. CT scanning cannot
differentiate benign from malignant SFTPs. The diagnostic
accuracy of CT-guided biopsy was 45% in our series
and thus, like other series, is considered unacceptably
low.13,16,18,21 Because of these variable results, we do not rou-
tinely recommend CT-guided biopsy. CT-guided biopsy
would be considered in patients at too high a risk for surgical
resection or patients with radiographically unresectable
masses to try and obtain a histopathologic diagnosis.
FIGURE 4. Computed tomographic scan showing a small solitary fibrous
tumor of the visceral pleura.
FIGURE 5. Computed tomographic scan showing a giant solitary fibrous
tumor of the pleura. It appears somewhat inhomogeneous.ery c July 2009
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SFTPs. VATS was used in only 14% of our patients, but this
clearly reflects the 30-year time span of this series, with
VATS being available only in the latter 15 years. The
median SFTP size for VATS resections was 2.4 cm (range,
0.8–15 cm), and there were no recurrences. The median
SFTP size for open resections was 7 cm (range, 1–30 cm).
Pulmonary wedge excision was the most common surgical
procedure, occurring in nearly three quarters of our patients,
and formal anatomic lung parenchymal resections alone
were performed in only 6 (7.1%) patients. Chest wall resec-
tion alone was required in 3 (3.6%) patients and was associ-
ated with an additional lung parenchymal resection in 6
more patients. The operative approach and extent of surgical
excision should be dictated by the SFTP’s size and location.
SFTPs in our series ranged in size from 0.8 to 30 cm, with
a median diameter of 5 cm. Size was the best clinical predic-
tor of malignancy, with malignant tumors having a median
diameter of 12 cm in comparison with 4.5 cm in benign
tumors (P ¼ .001).
Long-term survival after resection of both benign and
malignant SFTPs is possible, with the overall median sur-
vival in our series being 24 years. However, long-term sur-
vival for completely resected benign SFTPs is dramatically
better than that of completely resected malignant SFTPs
(Figure 2). Long-term follow-up after complete resection
is necessary because SFTPs can recur, and this was seen
in 8 (9.9%) of our patients, including 2 patients with benign
histopathology. Several authors have not reported recur-
rence after complete resection of benign SFTPs.11,13,16,18,21
In contrast, reported recurrence rates for completely resected
malignant SFTPs range from 14% to 86%.11,13,16,18 In our
series there were 10 surviving operative patients with malig-
nant SFTPs, and 6 (75%) of these experienced recurrence.
In only 3 patients (2 with benign SFTPs and 1 with a malig-
nant SFTP) was the recurrence localized to the same hemi-
thorax. After reoperation, recurrence again occurred in 2
patients.
In conclusion, SFTPs are uncommon tumors that are best
treated with complete surgical resection. In this series
increased tumor size is suggestive of malignancy. Long-
term survival after resection of benign SFTPs is excellent
but is also possible after resection for malignant SFTPs.
However, malignant SFTPs are prone to recurrence, which
in turn is associated with a poor prognosis.
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Discussion
Dr Robert J. Downey (New York, NY). Karen, I enjoyed that
very much.
SFTPs are going to be seen by all of us, but sporadically, such
that it is for most surgeons to get a sense for the disease. Therefore
I enjoy articles like this that flesh out their behavior based on large
institutional experiences.
I have 2 comments and 3 questions. My first comment is that
when I went over the data, it was clear I thought this would be an
excellent opportunity with a large data set of pathologic material
to re-examine the pathologic criteria for malignancy. I think that
your data validate England and colleagues’ data from 1989, which
established criteria for separating benign from malignant tumors in
that those criteria accurately predicted those patients of yours who
were likely to have recurrence and those who were not.
My second comment is that you noted that fine-needle aspiration
(FNA) only yielded a diagnosis in about 45% of patients, and the
article suggests that you do not recommend performing FNA before
surgical intervention. I would suggest that your study is not de-
signed to address this question because you do not know the de-
nominator of the patients with solitary pulmonary nodules who
underwent needle biopsy. Diagnoses of other types of tumors mightCardiovascular Surgery c Volume 138, Number 1 23
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you are eventually going to know that this tumor is a solitary fibrous
tumor, then you should not do a needle biopsy up front.
My questions are as follows. First, when these lesions are small,
operations are actually very easy. The large ones can be extremely
difficult, in that they can be hard to move around the chest, such that
you can have trouble finding the point of attachment, which is
clearly important for adequacy of resection. They can be hard to re-
move through an incision when they get up to 15 and 25 cm in size,
and they can be so large that they press against the boney structures
of the chest wall, develop venous engorgement, and bleed until the
chest is widely opened. You state only that these patients under-
went thoracotomies and sternotomies. Could you describe what ex-
tended approaches to the thorax, such as a hemiclamshell, you have
found useful in an attempt to achieve better exposure?
Second, some of the previous articles on benign fibrous tumors
have suggested that benign lesions can undergo malignant degener-
ation. Your data do not support this in that you saw only 1 patient
who had a recurrence that was read as malignant where the original
site of disease had been believed to be benign. To me, 1 transforma-
tion event in about 80 patients suggests that the problem is with the
adequacy of pathology, which in these other series might not have
been complete. These could be heterogeneous tumors, and if you
look carefully enough, you will eventually see the malignant
components.
Finally, based on the very poor outcomes seen in the patients
with malignant disease, are you recommending adjuvant therapy
once the resections have been completed?
Thank you.
Dr Harrison–Phipps. Thank you very much, Dr Downey, for
your comments and questions.
If I could just address one of your comments first, regarding the
FNA cytology, you correctly said that this had a positive predictive
value in 45% of our patients or that the sensitivity, rather, was cor-
rect in 45% of the patients, and this is pretty low. If you look
through a number of the series, the large series, in the majority of
them, it is really the minority of patients who have had a preopera-
tive FNA, but in no case series is the sensitivity higher than 45%,
and in some it is lower. I would say that there is 1 article that men-
tions that perhaps using a wide-bore, Tru-Cut biopsy needle might
result in improved diagnostic accuracy, but that was a small study
with only 5 patients. I think the problem that occurs is that it is dif-
ficult to decide whether they are benign or malignant solitary
fibrous tumors, and this is simply, as you said, because of the het-
erogeneity of the tumors. It would be easy to get an incorrect or
a sampling error.
Regarding the large tumors, in our series about a third of tumors
were larger than 15 cm, and in all our patients the resection was
complete. That is the first thing. When you look through the major-
ity of the case series, in fact, the majority of authors support the use
of a thoracotomy for resection of these tumors, and certainly there
are isolated case reports that describe a number of operative ap-
proaches for massive tumors, including hemiclamshell and so on.
We did use sternotomy in 3 patients, but, interestingly, those
were actually all for tumors of less than 10 cm, and it was just their
location and not the size that prompted the choice of this incision.
Therefore what I would say is that I truly advocate the use of the
hemiclamshell incision. I think it is an excellent incision with great24 The Journal of Thoracic and Cardiovascular Surexposure. It is just that we did not find it necessary in our series.
Our largest tumor was 30 cm, and in all cases all tumors were
removed through an extended posterolateral thoracotomy, if
necessary.
Regarding the transformation from benign to malignant, there
was only 1 such patient in our series. We did go back and ask the
pathologists to review the slides, and they confirmed that in fact
the original pathology was benign and the recurrence was malig-
nant. Various case series report no changes. I think the problem
is that these tumors are such a mixed bag, it really depends what
you are going to get. In some series the incidence is higher. I just
really think they are very individual tumors.
Regarding your question on adjuvant or neoadjuvant therapies,
chemotherapy or radiotherapy, there really are no data to make
any legitimate comment. There are certainly isolated comments
within oncology articles, and one in particular mentioned a patient
who had positive resection margins with an almost inoperable tu-
mor, an unresectable tumor. This patient had radiotherapy that
shrunk the tumor and was alive 20 years later. That was a benign
tumor. In another case a patient received adriamycin and isophos-
phamide and experienced some tumor shrinkage. But really, there
are no real data to support the use or choice of any regimen at all.
Dr P. Michael McFadden (Los Angeles, Calif). Dr Harrison–
Phipps, I have one question for you. You mentioned a number of
different tumor types that historically have been brought up: benign
mesotheliomas, solitary fibrous tumors, and others. Mesotheliomas
and these fibrous tumors can easily be differentiated now by using
immunohistochemical techniques. I was wondering whether you
verified the difference between the malignant tumors that you re-
moved and the 1 benign tumor that turned into a malignant tumor
on second biopsy using immunohistochemical techniques.
Dr Harrison–Phipps. Thank you, Dr McFadden, for your com-
ment and your question.
The study goes back to 1972, and therefore the first thing I would
say is that not all these immunohistochemical techniques were
available then, but in the majority of patients, the pathology reports
did include immunocytochemistry, and the markers that were
looked at were vimentin, cytokeratin, CD34, CD99, and Bcl-2.
As you correctly point out, malignant mesothelioma is positive
for cytokeratin but negative for these mesenchymal markers. The
thing is that it does not necessarily help you with deciding which
are benign and which are malignant. The only thing I can tell
you is that there might be some future markers that could help pre-
dict recurrence, and one of these is called p16, which has been
showing early promise at predicting recurrence with these solitary
fibrous tumors.
Dr Michael Lanuti (Boston, Mass). I enjoyed your presenta-
tion.
One of the things that I and perhaps my colleagues struggle with
is how to follow these patients. I would like your comments. I think
that a malignant phenotype is a bit easier, and you would probably
image them more frequently. In contrast, how often were patients
with a benign phenotype screened during follow-up in your study?
I struggle with how often one should image these patients because
there is a small risk of malignant degeneration.
Dr Harrison–Phipps. Thank you very much for your question.
I think I would come back to the sensitivity of the imaging.
Amazingly, chest radiographic analysis showed a sensitivity ofgery c July 2009
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what I would say is that for patients with malignant tumors, they
ought to be followed up for certain with a CT scan. I have some
data on the recurrences and when they recurred. Of the 6 patients
who experienced recurrence, the median time to recurrence was
37 months. Therefore you are predicting an early recurrence. The
range of that was quite significant. It was actually from 12 to 132
months. Therefore there was a wide range. I guess the bottom
line is that you have to be very vigilant at all times. It is very diffi-
cult to give you an exact answer, but I would certainly think that an
annual or at least a 6-month CT scan would be essential for patients
with malignant solitary fibrous tumors. I think it is easier for pa-
tients with benign tumors. You know, the risk of transformation
from a benign tumor to a malignant tumor is low, and personally,
I think an annual CT scan would be advisable. For people who
have health care economic issues, a chest radiographic scan is al-
most as good at 92% sensitivity, but I certainly think at least an an-
nual follow-up would be necessary for benign tumors and perhaps
a 6-month follow-up for malignant tumors.
Dr Jhingook Kim (Seoul, South Korea). We have reported
about 50 cases of our experience about 4 years ago. I have 3 ques-
tions or comments about how to approach these patients.
First of all, in my experience we do not have many patients who
require anatomic lung resection. This is the case for the SFTPs. In
most of the patients, we need just a wedge resection or otherwise
just to catch the tumor from the pleural cavity. In your report you
have so many pneumonectomies and lung resections.
Second, if the tumor is not so big, it is quite easy to just catch it.
However, if the tumor is fairly big, we can resect the tumor portion
by portion using small incisions. Because most of the fibrous tu-
mors are benign, there is no need to approach with such a big inci-
sion, including the hemiclamshell.
My third question is this: What do you think about the need for
neoadjuvant treatment if the tumor looks malignant or if the FNA
shows the malignancy?
Thank you for your attention.
Dr Harrison–Phipps. Thank you very much, Dr Kim.
With regard to your first question, in so many lung resections the
majority of the tumors are pedunculated, they arise from the vis-
ceral pleura, and they are on a stalk. I think the number of lung re-
sections was probably around 10 or less in total. The majority of our
excisions were wedge excisions. Seventy percent were wedge exci-
sions. Therefore I concur with what you say. But I would caution
you, because the bottom line is that you do not actually know the
pathology until you remove the specimen. One of our predecessors,
Dr Bernatz, has come up with a very useful comment, and he basi-
cally advises to consider the advice of the professional golfer to the
weekend golfer: do not underclub. Do not underestimate these tu-
mors. You have got to be careful. You want to take a little bit extra,
if you can.
With regard to your second question concerning no need for
large incisions for larger tumors, do I understand that you remove
these piecemeal? I was not quite sure what you were meaning there.
I understand you remove them bit by bit.The Journal of Thoracic andTo come back to the first comment, I certainly think the postero-
lateral thoracotomy is very useful for large tumors. You really want
to get all the tumor out, if you can. You are aiming for a clear re-
section margin. This is what the large case series of 232 patients
by England and colleagues supported. You are quite right to sug-
gest that the majority are very easy operations, some even using
VATS. It is a polypoid tumor that is easy to remove. But we
have to be careful with the larger ones because there is a risk of re-
currence, even with benign tumors, and the larger the tumors, obvi-
ously they could be malignant, and I really think that it is important
to think about your operative approach. In most cases a posterolat-
eral thoracotomy would be fine, but perhaps there are arguments for
more extended operations as well.
As for the need for neoadjuvant treatment, I do not know
whether we will ever get to know this. First of all, the tumors are
very rare. A preoperative diagnosis is hard to establish, certainly
for malignant tumors. You would never get it on the basis of an in-
adequate or uncertain report, and it is really unusual for an FNA to
diagnose a malignant SFTP preoperatively. Therefore I am not
sure we will ever see many patients who have had neoadjuvant
treatment.
Dr Jean Deslauriers (Quebec City, Quebec, Canada). This is
an academic question really. These tumors classically are associ-
ated with paraneoplastic syndromes, such as clubbing and hypo-
glycemia. In fact, the classic presentation is that it is a big tumor
with clubbing. Maybe you mentioned it in your presentation, but
I did not hear it. What percentage of these patients really had
one or the other classic paraneoplastic syndromes, such as club-
bing, and does this have an effect on whether the tumor is be-
nign at the end of the day or malignant? Because this is one
of the largest, if not the largest, series of such tumors, I would
be interested to know the exact incidence of these paraneoplastic
syndromes, if you were able to look at that aspect of these
tumors.
Dr Harrison–Phipps. Thank you very much for your question,
Dr Deslauriers.
The incidence of hypertrophic pulmonary osteoarthropathy in
this series was 8 patients, or 9.9%; the incidence of persons with
clubbing was 3 patients; and the incidence of hypoglycemia was
1 patient. You quite rightly mentioned these names, and these
names have syndromes in the literature. Hypoglycemia is known
as the Doege–Potter syndrome and hypertrophic pulmonary osteo-
arthropathy, and clubbing is known as the Pierre–Marie–Bamberg
syndrome. In our series it was 10% for these symptoms. That is
pretty much what you can find in the other series as well. There
are 1 or 2 series with more or less, but really, in our series, of those
8 patients or 9 with hypoglycemia who had these symptoms, only 2
were malignant. Therefore I do not really think we can say it pre-
dicts malignancy. It is simply due to the fact that for osteoarthrop-
athy, they might have an excess production of hyaluronic acid, and
for hypoglycemia, they have an excess production of insulin 2
growth–like factor. It is difficult to say. I do not necessarily think
it is related to size or malignancy. It is just a very interesting feature
of these unusual tumors.Cardiovascular Surgery c Volume 138, Number 1 25
